Quotes 5-day view Delayed Nasdaq
01/23/2023
01/24/2023
01/25/2023
01/26/2023
01/27/2023
Date
258.84(c)
260.42(c)
265.92(c)
264.23(c)
259.68(c)
Last
269 612
196 443
360 747
246 713
217 997
Volume
-1.09%
+0.61%
+2.11%
-0.64%
-1.72%
Change
Estimated financial data (e) (USD)
Sales 2022
1 966 M
-
-
Net income 2022
821 M
-
-
Net cash position 2022
692 M
-
-
P/E ratio 2022
15,3x
Yield 2022
-
Sales 2023
2 221 M
-
-
Net income 2023
946 M
-
-
Net cash position 2023
1 601 M
-
-
P/E ratio 2023
13,5x
Yield 2023
-
Capitalization
11 835 M
11 835 M
-
EV / Sales 2022
5,67x
EV / Sales 2023
4,61x
Nbr of Employees
965
Free-Float
62,0%
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat ulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil)...
Ratings of United Therapeutics Corporation
All news about UNITED THERAPEUTICS CORPORATION
News in other languages on UNITED THERAPEUTICS CORPORATION
Analyst Recommendations on UNITED THERAPEUTICS CORPORATION
ETFs positioned on UNITED THERAPEUTICS CORPORATION ETFs and Trackers with Trackinsight
Chart UNITED THERAPEUTICS CORPORATION
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends UNITED THERAPEUTICS CORPORATION
Short Term Mid-Term Long Term Trends Bearish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
259,68 $
Average target price
279,92 $
Spread / Average Target
7,80%
Please enable JavaScript in your browser's settings to use dynamic charts.